HC Wainwright Issues Optimistic Forecast for TCRX Earnings

TScan Therapeutics, Inc. (NASDAQ:TCRX) – Analysts at HC Wainwright lifted their Q1 2026 earnings per share estimates for shares of TScan Therapeutics in a note issued to investors on Wednesday, March 4th. HC Wainwright analyst A. Maldonado now forecasts that the company will post earnings of ($0.17) per share for the quarter, up from their previous estimate of ($0.20). HC Wainwright has a “Buy” rating and a $7.00 price objective on the stock. The consensus estimate for TScan Therapeutics’ current full-year earnings is ($1.12) per share. HC Wainwright also issued estimates for TScan Therapeutics’ Q2 2026 earnings at ($0.18) EPS, Q3 2026 earnings at ($0.19) EPS, Q4 2026 earnings at ($0.20) EPS, FY2026 earnings at ($0.76) EPS, FY2027 earnings at ($0.79) EPS, FY2028 earnings at ($0.74) EPS and FY2029 earnings at ($0.49) EPS.

TCRX has been the topic of several other reports. Weiss Ratings reissued a “sell (d-)” rating on shares of TScan Therapeutics in a research report on Thursday, January 22nd. Wedbush increased their price target on shares of TScan Therapeutics from $4.00 to $5.00 and gave the stock an “outperform” rating in a research note on Thursday. Finally, Morgan Stanley lowered shares of TScan Therapeutics from an “overweight” rating to an “equal weight” rating in a report on Friday, November 14th. Four investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, TScan Therapeutics has an average rating of “Hold” and an average price target of $6.20.

TScan Therapeutics Trading Up 4.6%

NASDAQ TCRX opened at $1.13 on Friday. TScan Therapeutics has a 12 month low of $0.88 and a 12 month high of $2.57. The company has a 50-day moving average of $1.06 and a 200-day moving average of $1.40. The company has a debt-to-equity ratio of 0.23, a current ratio of 6.44 and a quick ratio of 6.44. The company has a market cap of $64.13 million, a P/E ratio of -1.13 and a beta of 1.03.

TScan Therapeutics (NASDAQ:TCRX) last released its earnings results on Wednesday, March 4th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.09. TScan Therapeutics had a negative return on equity of 73.32% and a negative net margin of 1,256.81%.The firm had revenue of $2.57 million during the quarter.

Institutional Investors Weigh In On TScan Therapeutics

Large investors have recently modified their holdings of the stock. Y Intercept Hong Kong Ltd acquired a new position in TScan Therapeutics during the 2nd quarter worth approximately $111,000. Marshall Wace LLP grew its holdings in TScan Therapeutics by 627.5% during the 4th quarter. Marshall Wace LLP now owns 339,240 shares of the company’s stock valued at $339,000 after purchasing an additional 292,610 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in TScan Therapeutics by 6.0% during the 1st quarter. Goldman Sachs Group Inc. now owns 170,349 shares of the company’s stock worth $235,000 after buying an additional 9,676 shares during the period. XTX Topco Ltd boosted its position in TScan Therapeutics by 1,142.5% in the 4th quarter. XTX Topco Ltd now owns 219,001 shares of the company’s stock valued at $219,000 after buying an additional 201,375 shares during the last quarter. Finally, Virtu Financial LLC grew its stake in shares of TScan Therapeutics by 431.1% during the third quarter. Virtu Financial LLC now owns 60,480 shares of the company’s stock valued at $110,000 after acquiring an additional 49,092 shares in the last quarter. Institutional investors and hedge funds own 82.83% of the company’s stock.

Insider Transactions at TScan Therapeutics

In related news, major shareholder Lynx1 Capital Management Lp acquired 75,500 shares of the business’s stock in a transaction on Monday, December 22nd. The shares were bought at an average cost of $0.90 per share, with a total value of $67,950.00. Following the completion of the transaction, the insider directly owned 8,012,916 shares of the company’s stock, valued at $7,211,624.40. This trade represents a 0.95% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last three months, insiders acquired 161,801 shares of company stock valued at $145,621. 4.35% of the stock is currently owned by corporate insiders.

TScan Therapeutics Company Profile

TScan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan’s approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins.

The company’s pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors.